A Phase II Study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial)
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms AB7
- 10 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2022 Planned End Date changed from 1 Jul 2024 to 1 Oct 2025.
- 09 Sep 2022 Planned primary completion date changed from 1 May 2023 to 1 Oct 2024.